Advertisement

Introduction

  • Dennis V. CokkinosEmail author
Chapter

Abstract

The heart of an individual is in constant danger from the onset of fetal life, through adolescence, middle age and in senility. Efforts to prevent or manage all these risks of cardiac structure and function are constantly progressing depending on the collaboration of all scientific disciplines. Thus, instead of this incidental cardiac “protection”, the term “myocardial preservation” is proposed.

Keywords

Congenital heart defects Autopsy Molecular autopsy Sudden unexpected death Ischemic heart disease 

References

  1. 1.
    Wells GA. Goethe and the inter maxillary bone. Br J Hist Sci. 1967;3:348–61.CrossRefGoogle Scholar
  2. 2.
    Johann Wolfgang von Goethe Faust I (Studierzimmer II).Google Scholar
  3. 3.
    Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380:2095–128.CrossRefGoogle Scholar
  4. 4.
    Angelini P, Uribe C, Masso A, et al. Results of MRI-based screening study of 5130 candidates for sports participation. Am Coll Cardiol. 2017 Scientific Sessions:401–10.Google Scholar
  5. 5.
    Morentin B, Suárez-Mier MP, Aguilera B. Sudden unexplained death among persons 1-35 years old. Forensic Sci Int. 2003;135:213–7.CrossRefGoogle Scholar
  6. 6.
    Eckart RE, Scoville SL, Campbell CL, Shry EA, Stajduhar KC, Potter RN, et al. Sudden death in young adults: a 25-year review of autopsies in military. Ann Intern Med. 2004;141:829–34.CrossRefGoogle Scholar
  7. 7.
    Balady GJ. Sudden cardiac death in young military recruits: guarding the heart of a soldier. Ann Intern Med. 2004;141:882–4.CrossRefGoogle Scholar
  8. 8.
    Tester DJ, Ackerman MJ. The role of molecular autopsy in unexplained sudden cardiac death. Curr Opin Cardiol. 2006;21:166–72.CrossRefGoogle Scholar
  9. 9.
    Ackerman MJ. State of postmortem genetic testing known as the cardiac channel molecular autopsy in the forensic evaluation of unexplained sudden cardiac death in the young. Pacing Clin Electrophysiol. 2009;32(Suppl 2):S86–9.CrossRefGoogle Scholar
  10. 10.
    Torkamani A, Muse E, Spencer E, Rueda M, Wagner GN, Lucas JR, et al. Molecular autopsy for sudden unexpected death. JAMA. 2016;316:1492–4.CrossRefGoogle Scholar
  11. 11.
    Semsarian C, Ingles J. Molecular autopsy in victims of inherited arrhythmias. J Arrhythm. 2016;32:359–65.CrossRefGoogle Scholar
  12. 12.
    Hellenthal N, Gaertner-Rommel A, Klauke B, Paluszkiewicz L, Stuhr M, Kerner T et al. Molecular autopsy of sudden unexplained deaths reveals genetic predispositions for cardiac diseases among young forensic cases. ESC 17 Oct 2016.Google Scholar
  13. 13.
    Stattin EL, Westin IM, Cederquist K, et al. Genetic screening in sudden cardiac death in the young can save future lives. Int J Legal Med. 2016;130:59–66.CrossRefGoogle Scholar
  14. 14.
    Gago-Díaz M, Ramos-Luis E, Zoppis S, Zorio E, Molina P, Braza-Boïls A, et al. Postmortem genetic testing should be recommended in sudden cardiac death cases due to thoracic aortic dissection. Int J Legal Med. 2017;131:1211–9.CrossRefGoogle Scholar
  15. 15.
    Enos WF, Holmes RH, Beyer J. Coronary disease among United States soldiers killed in action in Korea; preliminary report. J Am Med Assoc. 1953;152:1090–3.CrossRefGoogle Scholar
  16. 16.
    McGill HC, McMahan CA, Zieske AW, et al. Association of Coronary Heart Disease Risk Factors with microscopic qualities of coronary atherosclerosis in youth. Circulation. 2000;102:374–9.CrossRefGoogle Scholar
  17. 17.
    Zhang X, Khan AA, Haq EU, Rahim A, Hu D, Attia J, et al. Increasing mortality from ischaemic heart disease in China from 2004 to 2010: disproportionate rise in rural areas and elderly subjects. 438 million person-years follow-up. Eur Heart J Qual Care Clin Outcomes. 2017;3:47–52.CrossRefGoogle Scholar
  18. 18.
    Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the global burden of disease study 2015. Lancet. 2016;388:1459–544.Google Scholar
  19. 19.
    The top 10 causes of death. WHO Updated January 2017.Google Scholar
  20. 20.
    Heron M. Deaths: leading causes for 2014. Natl Vital Stat Rep. 2016;65:1–96.PubMedGoogle Scholar
  21. 21.
    National Center for Health Statistics (NCHS). US Life Expectancy Drops for First Time Since 1999. December 08, 2016.Google Scholar
  22. 22.
    Fassa AA, Himbert D, Vahanian A. Mechanisms and management of TAVR-related complications. Nat Rev Cardiol. 2013;10:685–95.CrossRefGoogle Scholar
  23. 23.
    Paradis JM, Maniar HS, Lasala JM, Kodali S, Williams M, Lindman BR, et al. Clinical and functional outcomes associated with myocardial injury after transfemoral and transapical transcatheter aortic valve replacement: a subanalysis from the partner trial (placement of aortic transcatheter valves). JACC Cardiovasc Interv. 2015;8:1468–79.CrossRefGoogle Scholar
  24. 24.
    Filippo O, Marcello G, Donatella F, Francesco S, Patrizia L, et al. Prodromal angina limits infarct size. A role for Ischemic Preconditioning. Circulation. 1995;91:291–7.CrossRefGoogle Scholar
  25. 25.
    Iliodromitis E, Andreadou I, Dagres N, Kremastinos D. Pre- peri- post-conditioning the ischemic myocardium: challenges, confounders and expectations. In: Cokkinos DV, editor. Introduction to translational cardiovascular research. Cham: Springer; 2015. p. 541–52.Google Scholar
  26. 26.
    Cung T-T, Morel O, Cayla G, Rioufol G, Garcia-Dorado D, Angoulvant D, et al. Cyclosporine before PCI in patients with acute myocardial infarction. N Engl J Med. 2015;373:1021–31.CrossRefGoogle Scholar
  27. 27.
    Ottani F, Latini R, Staszewsky L, La Vecchia L, Locuratolo N, Sicuro M, et al. Cyclosporine a in reperfused myocardial infarction: the multicenter, controlled, open-label CYCLE trial. J Am Coll Cardiol. 2016;67:365–74.CrossRefGoogle Scholar
  28. 28.
    Werner GS, Lang K, Kuehnert H, Figulla HR. Intracoronary verapamil for reversal of no-reflow during coronary angioplasty for acute myocardial infarction. Catheter Cardiovasc Interv. 2002;57:444–51.CrossRefGoogle Scholar
  29. 29.
    Cokkinos DV. Le remodelage cardiaque après un infarctus : nouvelles données sur la prévention et le traitement. Bull Acad Natle Med. 2015;199:1383–94.Google Scholar
  30. 30.
    Tokita Y, Tang XL, Li Q, Wysoczynski M, Hong KU, Nakamura S, et al. Repeated administrations of cardiac progenitor cells are markedly more effective than a single administration: a new paradigm in cell therapy. Circ Res. 2016;119:635–51.CrossRefGoogle Scholar
  31. 31.
    Greenberg B, Butler J, Felker M, Ponikowski P, Voors A, Desai A, et al. Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. N Engl J Med. 2016;387:1178–86.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Heart and Vessel DepartmentBiomedical Research Foundation, Academy of Athens - Gregory SkalkeasAthensGreece

Personalised recommendations